Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 13/20 | 0.61 |
| ▸ | CA2 | P00918 | 13/20 | 0.61 |
| ▸ | CA12 | O43570 | 7/20 | 0.61 |
| ▸ | CA9 | Q16790 | 7/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CCNC | P24863 | 1/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10191081 | 1.00 | CA1 (0.61) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL29040473 | 1.00 | CA1 (0.61) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL29040417 | 1.00 | CA1 (0.61) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL29040410 | 1.00 | CA1 (0.61) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL16930099 | 1.00 | CA1 (0.61) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL23835564 | 1.00 | CA1 (0.61) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL2822013 | 0.99 | CA1 (0.60) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL487585 | 0.95 | CA1 (0.59) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL17162051 | 0.94 | CA1 (0.55) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL22326309 | 0.92 | CA1 (0.56) | CA1CA2CA12CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2024237721-A1 | NOVEL COMPOUNDS CAPABLE OF INDUCING OSTEOGENIC DIFFERENTIATION | 아주대학교산학협력단 | 2024-11-21 | — | — | WO | disclosed |
| CN-118176194-A | Conjugates comprising covalent binding agents for targeting intracellular proteins | 瑞择生物公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-117964623-A | Targeted protein degradation compound and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-115244053-B | Targeted protein degradation compound and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2024-01-30 | — | — | CN | disclosed |
| US-20230263903-A1 | PYRAZOLOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230263903-A1 | PYRAZOLOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230263903-A1 | PYRAZOLOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230226195-A1 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20150210682-A1 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150210682-A1 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-07-30 | — | — | US | disclosed |
| WO-2015012067-A1 | METAL COMPLEX, ADSORBENT, SEPARATING MATERIAL, AND 1, 3-BUTADIENE SEPARATION METHOD | 昭和電工株式会社 (JP) | 2015-01-29 | — | — | WO | disclosed |
| US-20150031674-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| WO-2015011252-A1 | PYRIMIDINE-PYRIDINONE SERINE/THREONINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-01-29 | — | — | WO | disclosed |
| EP-0853084-B1 | Substituted purine derivatives as vitronectin receptor antagonists | HOECHST AG (DE) | 2008-08-13 | — | — | EP | disclosed |
| US-6723727-B1 | VITRONECTIN RECEPTOR ANTAGONISTS; INHIBITORS OF BONE RESORPTION; OSTEOPOROSIS | HOECHST AKTIENGESELLSCHAFT (DE) | 2004-04-20 | — | — | US | disclosed |
| US-6191273-B1 | 3,6,10,14-SUBSTITUTED-3,6,10,16-TETRAAZABICYCLO(10.3.1)-HEXADE CA-1(16),12,14-TRIENE COMPOUNDS OF GIVEN FORMULA; ANTIBACTERIAL AND OTHER UTILITIES, SUCH AS TO SCREEN FOR PESTICIDES OR DRUGS | ISIS PHARMACEUTICALS, INC. | 2001-02-20 | — | — | US | disclosed |
| EP-0853084-A2 | Substituted purine derivatives as vitronectin receptor antagonists | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-07-15 | — | — | EP | disclosed |
| EP-0278621-B1 | SUBSTITUTED AMINE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1991-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | CA1 4427/4885CA2 4454/4885CA12 4552/4885 |
| US-20230263903-A1 | PYRAZOLOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | KCNJ5, IL5, CYP3A5 | CA1 157/4885CA2 498/4885CA12 410/4885 |
| US-20150210682-A1 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HAVCR2, HCCS, DHX15 | CA1 4852/4885CA2 4881/4885CA12 4685/4885 |
| US-20150031674-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, RB1 | CA1 4083/4885CA2 3870/4885CA12 4846/4885 |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | CA1 4801/4885CA2 3902/4885CA12 4633/4885 |
| US-20230226195-A1 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | SNCA, ADRM1, UBE3C | CA1 4596/4885CA2 4743/4885CA12 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.